Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.

Israel journal of medical sciences - 1 Jan 1990

Rahav G, Zylber-Katz E, Rachmilewitz D, Levy M

Abstract excerpt

We examined 122 patients with inflammatory bowel disease treated with salicylazosulfapyridine. Forty-two (34.5%) had adverse effects that led to discontinuation of therapy in 14 (11.5%). In 33 patients the effects appeared to be dose dependent. The plasma sulfapyridine levels in patients exhibiti...

Topics

Acetylation
Adolescent
Adult
Aged
Chronic Disease
Dose-Response Relationship, Drug
Female
Humans
Inflammatory Bowel Diseases
Male
Middle Aged
Nausea

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Phenotype

Retrospective Studies

Sulfanilamides

Sulfapyridine

Sulfasalazine

Time Factors

Source

Open in PubMed

Identifiers

PMID: 1968894

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-1968894-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.PMID 1968894Read ↗

Clinical pharmacokinetics of sulphasalazine.Semantic proximity Read ↗

N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.Semantic proximity Read ↗

N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.Semantic proximity Read ↗

N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events.Semantic proximity Read ↗

Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions.Semantic proximity Read ↗

Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.Semantic proximity Read ↗

Expression of monomorphic and polymorphic N-acetyltransferases in human colon.Semantic proximity Read ↗

[Axonal neuropathy and salazosulfapyridine: slow-acetylator phenotype].Semantic proximity Read ↗

Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine.Semantic proximity Read ↗

Formation and elimination of sulphamethoxazole hydroxylamine after oral administration of sulphamethoxazole.Semantic proximity Read ↗

N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.Semantic proximity Read ↗

Acetylator phenotype in patients with allergic diseases and its clinical significance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.